Associated Papers
α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia.
Millman SE et al.
Blood, 2025
Succinate dehydrogenase variants in paraganglioma: why are B subunit variants 'bad'?
Gruber LM et al.
Endocrine Oncology (bristol, England), 2023
37434649 (PubMed )
Supplement: supplementary_table_1.xlsx › Missense_Variants
Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL et al.
Oncotarget, 2015
Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism.
Aspuria PP et al.
Cancer & Metabolism, 2014
No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma.
Montani M et al.
Endocrine-related Cancer, 2005
Genetics of neuroendocrine and carcinoid tumours.
Leotlela PD et al.
Endocrine-related Cancer, 2003
Select a paper to view details